Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Medicare Revamps Competitive Bidding Program
The Centers for Medicare & Medicaid Services is preparing to revive competitive bidding program for durable medical equipment that industry members helped sink last summer when it was originally scheduled to take effect, CQ HealthBeat reports. The agency had anticipated a 26 percent savings for wheelchairs, oxygen tanks and other pieces of equipment through the program. But a lobbying group for the suppliers, the American Association for Homecare, successfully urged Congress to shut down the program before it went into effect.

Theratechnologies Presents Results From A Pharmacokinetic/Phamacodynamic Evaluation Of Tesamorelin At The Endocrine Society's Annual Meeting
Theratechnologies (TSX:TH) announced today that results from a pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tesamorelin were presented as a poster (Poster number: P3-641) at the Endocrine Society"s 91st Annual Meeting in Washington D.C. Tesamorelin is an analogue of the growth hormone releasing factor evaluated for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
News of the day
What Is Fungus? What Are Fungi?
Fungi (Singular: fungus) are classified within their own kingdom - The Kingdom Fungi, while some are in The Kingdom Protista. A fungus is neither a plant nor an animal. It is similar to a plant, but it has no chlorophyll and cannot make its own food like a plant can through photosynthesis. They get their food by absorbing nutrients from their surroundings.
Diagnostics

Gendux Molecular Limited Withdraws Its Marketing Authorisation Application For Contusugene Ladenovec Gendux (contusugene Ladenovec)

The European Medicines Agency has been formally notified by Gendux Molecular Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine Contususgene ladenovec Gendux (contusugene ladenovec), suspension for injection. Contusugene ladenovec Gendux was expected to be used for the treatment of squamous cell carcinoma in head and neck cancer. The application for the marketing authorisation for Contususgene ladenovec Gendux was submitted to the Agency on 2 July 2008. At the time of withdrawal, it was under review by the Agency"s Committee for Medicinal Products for Human Use (CHMP). In its official letter, the company stated that the withdrawal of the application was based on the difficult financial situation of its parent company Introgen Therapeutics, Inc., which prohibits them to fund further activities related to this application. More information about Contusugene ladenovec Gendux and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website shortly. European Medicines Agency


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009